In addition, in NSCLC patients who developed acquired drug resistance after single anti-PD-1 or anti-PD-1 combined with anti-CTLA-4 therapy, the loss of neoantigens has been found based on complete exome sequencing of tumor cells (131). Here, PDCD1 is linked to non-small cell lung carcinoma.